Naxitamab is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat people one year of age and older with high-risk neuroblastoma in bone or bone marrow whose tumor did not respond to or has come back after previous treatments and has shown a partial response, minor response, or stable disease to prior therapy.<\/p>\n
Naxitamab, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy. The U.S. Food and Drug Administration (FDA) granted the application for naxitamab priority review, breakthrough therapy, and, orphan drug designations. The FDA issued a priority review voucher for this rare pediatric disease product application and was later granted a priority approval.<\/p>\n
To access naxitamab-gqgk injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Danyelza (naxitamab-gqgk injection) for intravenous use Initial U.S. Approval: 2020<\/p>\n","protected":false},"excerpt":{"rendered":"
Danyelza (naxitamab-gqgk) is a medication used to treat children aged 1 year or older and adults with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.<\/p>\n
DISEASE INDICATIONS-Neuroblastoma If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cnaxitamab-gqgk injection\u201d based on the information you provide.<\/p>\n
\nMANUFACTURER-Y-mAbs Therapeutics
\nUSAGE-Intravenous
\nDosage Forms and Strengths: Injection: 40 mg\/10 mL (4 mg\/mL) in a single-dose vial.
\nMEDICINE APPROVED BY-Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n